Corporate
News release
TopTOKYO, JAPAN - February 28, 2019 - Terumo Corporation (TSE: 4543) today announced that it will begin selling the Dexcom G4™ PLATINUM Continuous Glucose Monitoring System in Japan. U.S.-based DexCom, Inc., manufactured the product and Terumo has the right to distribute it exclusively in Japan.
The Dexcom G4™ PLATINUM is a medical system for people with diabetes that continuously monitors the glucose level in the interstitial fluid of subcutaneous tissues. Dexcom is a global market leader in real-time CGM, and its products stand out for their high accuracy and a safety mechanism that automatically alerts the user when the level of blood glucose is too low or too high.
Diabetes may lead to: loss of patients' eyesight, kidney disease, myocardial infarction or stroke. Terumo positions the launch of the CGM as an important milestone in contributing to diabetes therapy. The company plans to commence nationwide sales of Dexcom's CGM with Terumo's self-monitoring blood glucose system, and Japan's first tubing-free insulin patch pump. Meanwhile, Terumo will continue to launch Dexcom's next-generation CGM systems as each new model becomes available in Japan.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.